Qiagen announced three separate agreements that add biomarkers to its diagnostic pipeline for personalized health care applications to guide treatments with various medicines based on a patient’s genomic information.
Qiagen will develop solutions to guide treatment decisions based on these biomarkers for use in rheumatoid arthritis, lung cancer, and colorectal cancer. Most of these assays will run on the QIAsymphony RGQ laboratory automation system as well as Qiagen’s NGS workflows now being developed.
Qiagen has invested in Drug Response Dx GmbH, with the option to obtain worldwide rights to biomarkers for evaluation of rheumatoid arthritis patients to guide treatment with TNF-alpha inhibitors.
Qiagen has agreed to license exclusive worldwide rights from Insight Genetics for the RET, ROS1, and DEPDC1 biomarkers for use in nonsmall cell lung cancer.
Qiagen Marseille has licensed exclusive worldwide rights to a biomarker for mutations of the HSP110 gene, which allows for identification of specific types of colorectal cancer, from InsermTransfert, the technology transfer arm of the French National Institute of Health and Medical Research in Paris.
Qiagen will develop the biomarkers into a diagnostic test from routine use in the diagnostic workup of colorectal cancer patients.
Qiagen, 800-426-8157